Novel Inhibitors of Glucose Transporter 1 for Cancer
AJAS · 2017 Biomedical and Health Sciences (inferred)
Overview
The goal of the project was to identify effective targeted drugs for inhibiting Protein Glucose Transporter 1 (GLUT1). Findings would be a big step towards curing cancer. GLUT1 transports glucose across the cell membrane, plays an important role during several stages of cancer progression, and is essential to the survival of many types of cancer. After reviewing existing docking research on the 4 known inhibitors of GLUT1, 23 docking positions were determined and then tested in 10 trials. The best docking position identified was then used for a High Throughput Molecular Docking Study of 47 million ligands with GLUT1. Thousands of ligands found had much more effective docking results than the 4 existing drugs. Top novel-inhibitor candidates (40%-63% improvement in binding free energy compared to existing inhibitors) were chosen after toxicity-testing and 5 trials of tests with 7 optimal-docking positions. BJD000029 and BJD000021 are two great examples of new ligands designed through structural manipulation. The methodology used in this experiment streamlined the hit to lead process. An important discovery of this experiment is Merck Pharmaceuticals’ Akt inhibitor MK-2206’s potential as a GLUT1 inhibitor. It had lower Gibbs free energy than any existing GLUT1 inhibitor. Currently, it’s in phase II of clinical trials. Based on 10 trials of tests and evaluation of toxicity, lipophilicity, solubility, a top 10 list of novel candidate-inhibitors was created. Among them, ZINC08918302, ZINC16847726 and MK-2206 were selected for testing in cancer cell cultures. One great advantage of the top novel candidate-inhibitors is that they all successfully passed the toxicity check, unlike the existing inhibitors.
Competition history
- AJAS 2017
Related projects
ISEF · 2016
Novel Inhibitors of Glucose Transporter 1 (GLUT1) for Cancer
ISEF · 2018
Identifying Metabolic Inhibitors to Target Aggressive Cancers with Deregulated p27kip1
ISEF · 2016
A Novel Approach to Cancer Treatment: Allosteric Inhibition of the Carbonic Anhydrase IX Isozyme for Anticancer Applications
CSEF · 2018
Synthesizing Inhibitors of Isocitrate Dehydrogenase 1 to Inhibit Glutamine-Dependent Reductive Carboxylation in Tumors
ISEF · 2023
Developing a Selective SUV39H1 Inhibitor to Improve Cancer Prognosis
ISEF · 2026
Analysis of MCT2 as a Selective Therapeutic Target in Cancer Metabolism
CSEF · 2017
Efficacy of BIBR1532 in Combination with Nutrient Deprivation on Reduction of Cell Viability in MCF7 and HT1080
ISEF · 2025
Discovery and Structure-Based Optimization of Highly Selective PTP1B Inhibitors: A Multi-Stage in silico Workflow Integrating Machine Learning for Ligand-Based Virtual Screening and Molecular Docking & Dynamics Simulations To Enhance Insulin Sensitivity in Type-2 Diabetes
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: AAAS Annual Meeting (Confex) / American Junior Academy of Science